Actively Recruiting
Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists
Led by Olistic Research Labs S.L. · Updated on 2026-03-23
40
Participants Needed
1
Research Sites
32 weeks
Total Duration
On this page
Sponsors
O
Olistic Research Labs S.L.
Lead Sponsor
G
Grupo Dermatologico Y Estetico Pedro Jaen S.A.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1/GIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.
CONDITIONS
Official Title
Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female gender
- Age over 35 years
- Started treatment with a GLP-1/GIP agonist or treatment duration less than 3 months
- Signed informed consent after being informed about the study
- Additional criteria as specified by the study sponsor
You will not qualify if you...
- Allergy or sensitivity to the supplement components or similar products
- Presence of scalp diseases such as cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, or cancer
- Alopecia caused by underlying medical conditions like hypothyroidism, anemia, or lupus
- Use of medications that may cause telogen effluvium started within 3 months before the study
- Uncontrolled thyroid disorders within 6 months prior to study start
- Use of anti-hair loss products within the last 3 months
- Dermatological treatments for hair loss within the last 6 months
- Hair transplantation within 18 months prior to study start
- Initiation of anxiolytics, antidepressants, amphetamines, ACE inhibitors, or iron treatments within the last 3 months
- Initiation or discontinuation of hormonal treatments within the last 3 months
- Pregnancy, postpartum period within 6 months, breastfeeding, or planning pregnancy during the study
- Any condition making study participation inappropriate as judged by the investigator
- Additional exclusion criteria as specified by the study sponsor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Grupo Dermatologico Y Estetico Pedro Jaen S.A.
Madrid, Madrid, Spain, 28006
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here